Partnership aims to develop drugs for neurodegenerative diseases
Denali will draw on Lonza’s expertise in developing and manufacturing complex biologic molecules
BASEL, Switzerland and SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing.
A major hurdle for treating neurodegenerative diseases is the inability of most biologics to cross the tightly controlled blood-brain barrier (BBB). Denali is engineering its biologic product candidates to overcome this fundamental obstacle. Manufacturing these sophisticated therapies requires a tailor-made approach, together with expertise and agility in cell line, process and formulation development.
Read Full Article Here: https://globenewswire.com/news-release/2018/02/08/1336214/0/en/Denali-Therapeutics-and-Lonza-Pharma-Biotech-Announce-Exclusive-Partnership-to-Develop-and-Produce-Biologic-Medicines.html